This Article Full Text Full Text (PDF) All Versions of this Article: 46/1/113    most recent 01.HYP.0000171184.84077.80v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujita, M. Articles by Kitakaze, M. Search for Related Content PubMed PubMed Citation Articles by Fujita, M. Articles by Kitakaze, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Coronary circulation Related Article

(Hypertension. 2005;46:113.)
© 2005 American Heart Association, Inc.

Original Articles

Aldosterone Nongenomically Worsens Ischemia Via Protein Kinase C-Dependent Pathways in Hypoperfused Canine Hearts

Masashi Fujita; Tetsuo Minamino; Hiroshi Asanuma; Shoji Sanada; Akio Hirata; Masakatsu Wakeno; Masafumi Myoishi; Hiroko Okuda; Akiko Ogai; Ken-ichiro Okada; Osamu Tsukamoto; Hidekazu Koyama; Masatsugu Hori; Masafumi Kitakaze

From the Departments of Internal Medicine and Therapeutics (M.F., T.M., H.A., S.S., A.H., H.O., K.O., O.T., H.K, M.H.), and Bioregulatory Medicine (M.W., M.M.), Osaka University Graduate School of Medicine, Suita, Osaka; Cardiovascular Division of Medicine (A.O., M.K.), National Cardiovascular Center of Japan, Suita, Osaka, Japan.

Correspondence to Tetsuo Minamino, MD, PhD, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. E-mail minamino{at}medone.med.osaka-u.ac.jp

Rapid nongenomic actions of aldosterone independent of mineralocorticoid receptors (MRs) on vascular tone are divergent. Until now, the rapid nongenomic actions of aldosterone on vascular tone of coronary artery and cardiac function in the in vivo ischemic hearts were not still fully estimated. Furthermore, although aldosterone can modulate protein kinase C (PKC) activity, there is no clear consensus whether PKC is involved in the nongenomic actions of aldosterone on the ischemic hearts. In open chest dogs, the selective infusion of aldosterone into the left anterior descending coronary artery (LAD) reduced coronary blood flow (CBF) in the nonischemic hearts in a dose-dependent manner. Also, in the ischemic state that CBF was decreased to 33% of the baseline, the intracoronary administration of aldosterone (0.1 nmol/L) rapidly decreased CBF (37.4±3.8 to 19.3±5.2 mL/100 g/min; P<0.05), along with decreases in fractional shortening (FS) (8.4±0.7 to 5.4±0.4%; P<0.05) and lactate extraction rate (LER) (–31.7±2.9 to –41.4±3.7%; P<0.05). The decrease in CBF was reproduced by the infusion of bovine serum albumin-conjugated aldosterone. Notably, these aldosterone-induced deteriorations of myocardial contractile and metabolic functions were blunted by the co-administration of GF109203X, an inhibitor of PKC, but not spironolactone. In addition, aldosterone activated vascular PKC. These results indicate that aldosterone nongenomically induces vasoconstriction via PKC-dependent pathways possibly through membrane receptors, which leads to the worsening of the cardiac contractile and metabolic functions in the ischemic hearts. Elevation of plasma or cardiac aldosterone levels may be deleterious to ischemic heart disease through its nongenomic effects.

Key Words: aldosterone • ischemia • protein kinases

Related Article:

Rapid Effects of Aldosterone: Relevant in Cardiac Ischemia?

Martin Wehling
Hypertension 2005 46: 27-28. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]

				M. Yamada, M. Kushibiki, T. Osanai, H. Tomita, and K. Okumura Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization Cardiovasc Res, July 1, 2008; 79(1): 169 - 178. [Abstract] [Full Text] [PDF]

				R. Gros, Q. Ding, S. Armstrong, C. O'Neil, J. G. Pickering, and R. D. Feldman Rapid effects of aldosterone on clonal human vascular smooth muscle cells Am J Physiol Cell Physiol, February 1, 2007; 292(2): C788 - C794. [Abstract] [Full Text] [PDF]

				W. Chai, I. M. Garrelds, R. de Vries, and A.H. Jan Danser Cardioprotective Effects of Eplerenone in the Rat Heart: Interaction With Locally Synthesized or Blood-Derived Aldosterone? Hypertension, April 1, 2006; 47(4): 665 - 670. [Abstract] [Full Text] [PDF]

				N. Kobayashi, K. Yoshida, S. Nakano, T. Ohno, T. Honda, Y. Tsubokou, and H. Matsuoka Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat Hearts Hypertension, April 1, 2006; 47(4): 671 - 679. [Abstract] [Full Text] [PDF]

				E. L. Schiffrin Effects of Aldosterone on the Vasculature Hypertension, March 1, 2006; 47(3): 312 - 318. [Full Text] [PDF]

				M. Wehling Rapid Effects of Aldosterone: Relevant in Cardiac Ischemia? Hypertension, July 1, 2005; 46(1): 27 - 28. [Full Text] [PDF]